Common-Size Income Statement
Paying user area
Try for free
Abbott Laboratories pages available for free this week:
- Statement of Comprehensive Income
- Balance Sheet: Liabilities and Stockholders’ Equity
- Common-Size Balance Sheet: Assets
- Analysis of Reportable Segments
- Enterprise Value to FCFF (EV/FCFF)
- Capital Asset Pricing Model (CAPM)
- Operating Profit Margin since 2005
- Return on Equity (ROE) since 2005
- Current Ratio since 2005
- Total Asset Turnover since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Abbott Laboratories for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Abbott Laboratories, common-size consolidated income statement
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
| Income statement item | Description | The company |
|---|---|---|
| Operating earnings | The net result for the period of deducting operating expenses from operating revenues. | Abbott Laboratories operating earnings as a percentage of net sales decreased from 2022 to 2023 but then slightly increased from 2023 to 2024. |
| Earnings from continuing operations before taxes | Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. | Abbott Laboratories earnings from continuing operations before taxes as a percentage of net sales decreased from 2022 to 2023 but then slightly increased from 2023 to 2024. |
| Net earnings | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. | Abbott Laboratories net earnings as a percentage of net sales decreased from 2022 to 2023 but then increased from 2023 to 2024 exceeding 2022 level. |